Your browser is no longer supported. Please, upgrade your browser.
RGLS Regulus Therapeutics Inc. monthly Stock Chart
RGLS [NASD]
Regulus Therapeutics Inc.
Index- P/E- EPS (ttm)-0.53 Insider Own14.63% Shs Outstand107.92M Perf Week-1.42%
Market Cap76.62M Forward P/E- EPS next Y-0.51 Insider Trans0.00% Shs Float89.05M Perf Month0.07%
Income-31.70M PEG- EPS next Q-0.15 Inst Own52.90% Short Float1.26% Perf Quarter-15.48%
Sales0.07M P/S1064.21 EPS this Y69.40% Inst Trans-4.65% Short Ratio3.89 Perf Half Y-21.98%
Book/sh0.22 P/B3.23 EPS next Y12.10% ROA-92.80% Target Price1.75 Perf Year-27.18%
Cash/sh0.42 P/C1.70 EPS next 5Y39.60% ROE-214.40% 52W Range0.61 - 1.52 Perf YTD-31.73%
Dividend- P/FCF- EPS past 5Y25.90% ROI- 52W High-52.11% Beta1.76
Dividend %- Quick Ratio1.70 Sales past 5Y- Gross Margin- 52W Low18.76% ATR0.04
Employees63 Current Ratio1.70 Sales Q/Q0.00% Oper. Margin- RSI (14)56.34 Volatility8.70% 6.11%
OptionableYes Debt/Eq0.87 EPS Q/Q59.20% Profit Margin- Rel Volume0.32 Prev Close0.71
ShortableYes LT Debt/Eq0.00 EarningsMay 10 AMC Payout- Avg Volume288.36K Price0.73
Recom2.40 SMA201.56% SMA505.12% SMA200-26.52% Volume4,620 Change2.54%
Mar-28-18Initiated B. Riley FBR, Inc. Neutral $1
Jan-05-18Initiated Leerink Partners Outperform $2
Jun-13-17Reiterated Chardan Capital Markets Buy $5 → $2.50
Mar-06-17Reiterated Wedbush Outperform $8 → $6
Jan-30-17Downgrade Wells Fargo Outperform → Market Perform
Jan-30-17Downgrade Needham Buy → Hold
Dec-07-16Reiterated Chardan Capital Markets Buy $12 → $5
Nov-02-16Reiterated Needham Buy $10 → $9
Jul-25-16Reiterated Chardan Capital Markets Buy $14.50 → $12
Jun-28-16Reiterated Needham Buy $25 → $10
Jun-28-16Reiterated FBR Capital Outperform $30 → $9
Jun-28-16Reiterated Chardan Capital Markets Buy $20 → $13.50
Jun-07-16Reiterated Chardan Capital Markets Buy $15 → $20
Apr-13-16Initiated Chardan Capital Markets Buy $15
Dec-04-15Initiated Wells Fargo Outperform
Jun-09-15Initiated Guggenheim Buy
Apr-21-15Resumed FBR Capital Outperform $30
Nov-24-14Initiated Deutsche Bank Buy $30
Aug-07-14Reiterated FBR Capital Outperform $14 → $15
Aug-14-13Reiterated Needham Buy $8 → $12
Jun-12-18 07:45AM  New Research: Key Drivers of Growth for CNA Financial, AutoNation, Hess, Infinity Pharmaceuticals, Regulus Therapeutics, and Weyerhaeuser Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
May-17-18 07:40AM  Report: Developing Opportunities within Regulus Therapeutics, Airgain, Michael Kors, Heritage Insurance, CDK Global, and MedEquities Realty Trust Future Expectations, Projections Moving into 2018 GlobeNewswire
May-10-18 11:46PM  Edited Transcript of RGLS earnings conference call or presentation 10-May-18 9:00pm GMT Thomson Reuters StreetEvents
05:08PM  Regulus: 1Q Earnings Snapshot Associated Press
04:10PM  Regulus Reports First Quarter 2018 Financial Results and Pipeline Progress PR Newswire
May-03-18 04:15PM  Regulus to Provide First Quarter 2018 Financial Results on May 10, 2018 PR Newswire
May-01-18 08:30AM  Regulus Initiates Multiple Ascending Dose Study in Healthy Volunteers of RGLS4326 for the Treatment of ADPKD PR Newswire
Apr-17-18 04:10PM  Kathryn J. Collier Joins Regulus Board of Directors PR Newswire
Mar-20-18 04:15PM  Regulus to Present at the Needham Healthcare Conference PR Newswire
Mar-09-18 12:11AM  Edited Transcript of RGLS earnings conference call or presentation 7-Mar-18 10:00pm GMT Thomson Reuters StreetEvents +12.18%
Mar-07-18 04:31PM  Regulus reports 4Q loss Associated Press
04:10PM  Regulus Reports Fourth Quarter and Year-end 2017 Financial Results and Pipeline Update PR Newswire
01:00PM  Regulus Therapeutics Inc. to Host Earnings Call ACCESSWIRE
06:35AM  Was Regulus Therapeutics Incs (NASDAQ:RGLS) Earnings Decline A Part Of Broader Industry Downturn? Simply Wall St.
Mar-05-18 07:01PM  Regulus to Present at the Cowen and Company 38th Annual Health Care Conference PR Newswire
Mar-02-18 08:00AM  New Research: Key Drivers of Growth for New Media Investment Group, Perficient, Strayer Education, Regulus Therapeutics, Kelly Services, and Insys Therapeutics Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire +9.26%
Feb-28-18 04:15PM  Regulus to Provide Fourth Quarter and Year-end 2017 Financial Results on March 7, 2018 PR Newswire -5.13%
Feb-22-18 02:23AM  WuXi STA and Regulus Announce microRNA Development and Manufacturing Collaboration PR Newswire
Feb-08-18 04:15PM  Regulus to Participate in the LEERINK Partners 7th Annual Global Healthcare Conference PR Newswire
Jan-05-18 08:00AM  Analysis: Positioning to Benefit within Churchill Downs, Airgain, Fortune Brands Home & Security, Kemper, Perficient, and Regulus Therapeutics Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire +5.08%
Dec-19-17 08:30AM  Regulus Announces First-in-Human Dosing for Phase I Study of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease PR Newswire
Nov-13-17 06:10PM  Edited Transcript of RGLS earnings conference call or presentation 7-Nov-17 10:00pm GMT Thomson Reuters StreetEvents
Nov-07-17 06:36PM  Regulus reports 3Q loss Associated Press
04:10PM  Regulus Reports Third Quarter 2017 Financial Results and Recent Events PR Newswire
01:00PM  Regulus Therapeutics Inc. to Host Earnings Call ACCESSWIRE
Oct-31-17 04:15PM  Regulus to Provide Third Quarter 2017 Financial Results on November 7, 2017 PR Newswire -7.41%
Oct-03-17 08:53AM  Regulus Therapeutics (RGLS) Looks Good: Stock Adds 5.6% in Session Zacks +6.06%
Aug-30-17 04:15PM  Regulus to Present at the 2017 Wells Fargo Healthcare Conference PR Newswire
Aug-25-17 08:35AM  Are Options Traders Betting on a Big Move in Regulus Therapeutics (RGLS) Stock? Zacks -5.88%
Aug-13-17 12:35PM  Edited Transcript of RGLS earnings conference call or presentation 1-Aug-17 9:00pm GMT Thomson Reuters StreetEvents
Aug-08-17 05:00PM  Regulus to Present at the 2017 Wedbush PacGrow Healthcare Conference PR Newswire
Aug-01-17 09:40PM  Regulus reports 2Q loss Associated Press
04:10PM  Regulus Reports Second Quarter 2017 Financial Results and Recent Events PR Newswire
12:15PM  Investor Network: Regulus Therapeutics Inc. to Host Earnings Call ACCESSWIRE
Jul-25-17 09:15PM  Regulus Therapeutics Inc (RGLS) President and CEO Joseph P Hagan Bought $200,000 of Shares GuruFocus.com
04:05PM  Regulus Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares PR Newswire
08:30AM  Regulus to Provide Second Quarter 2017 Financial Results on August 1, 2017 PR Newswire
Jul-19-17 09:45PM  Regulus Announces Pricing of Public Offering of Common Stock PR Newswire
04:01PM  Regulus Announces Commencement of Public Offering of Common Stock PR Newswire
Jun-13-17 02:24PM  Chardan Capital Slashed Price Target on Regulus Therapeutics Inc (RGLS) Following Program Discontinuations SmarterAnalyst
01:12PM  Regulus, AstraZeneca Cut Ties on Liver Disease Treatment, Shares Dip TheStreet.com
08:30AM  Regulus Promotes Mark Deeg, M.D. PhD to Chief Medical Officer PR Newswire
Jun-12-17 07:00AM  Regulus Announces Pipeline Updates and Advancements PR Newswire -16.07%
Jun-08-17 08:00AM  Aptuit Announces Strategic Provider Agreement with Regulus Therapeutics PR Newswire
Jun-01-17 04:15PM  Pascale Witz Joins Regulus Board of Directors PR Newswire
May-17-17 07:05AM  Edited Transcript of RGLS earnings conference call or presentation 4-May-17 9:00pm GMT Thomson Reuters StreetEvents
May-11-17 04:30PM  Edited Transcript of RGLS earnings conference call or presentation 4-May-17 9:00pm GMT Thomson Reuters StreetEvents -6.06%
May-08-17 08:00AM  Q1 Losses Couldn't Drag Regulus or Corvus Pharmaceuticals Down Accesswire -5.56%
May-05-17 05:03AM  Regulus reports 1Q loss Associated Press +5.88%
May-04-17 04:30PM  Regulus Reports First Quarter 2017 Financial Results and Corporate Restructuring PR Newswire
Apr-27-17 04:10PM  Regulus to Provide First Quarter 2017 Financial Results on May 4, 2017 PR Newswire
Mar-31-17 12:46PM  DEADLINE APRIL 3: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus Therapeutics, Inc. and Reminds Investors with Losses to Contact the Firm GlobeNewswire
12:16PM  SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing in Regulus Therapeutics, Inc. to Contact the Firm Before Imminent Lead Plaintiff Deadline Accesswire
11:51AM  DEADLINE MONDAY: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Reminds Investors with Losses to Contact the Firm GlobeNewswire
11:21AM  RGLS DEADLINE ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Regulus Therapeutics Inc. and a Lead Plaintiff Deadline of April 3, 2017 GlobeNewswire
09:38AM  DEADLINE ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
08:58AM  SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Regulus Therapeutics, Inc. To Contact The Firm Before Imminent Lead Plaintiff Deadline PR Newswire
Mar-30-17 04:47PM  DEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Reminds Investors with Losses to Contact the Firm GlobeNewswire
01:35PM  SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Regulus Therapeutics, Inc. To Contact The Firm Before Imminent Lead Plaintiff Deadline GlobeNewswire
11:35AM  IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
10:10AM  DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Regulus Therapeutics Inc. (RGLS) & Lead Plaintiff Deadline - April 3, 2017 GlobeNewswire
Mar-28-17 03:18PM  IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Regulus Therapeutics Inc. and Encourages Investors With Losses to Contact the Firm Business Wire -11.76%
12:36PM  INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Commenced a Class Action on Behalf of Shareholders of Regulus Therapeutics Inc. -- Lead Plaintiff Deadline of April 3, 2017 GlobeNewswire
08:30AM  Regulus to Present at the 16th Annual Needham Healthcare Conference PR Newswire
Mar-27-17 06:05PM  SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Regulus Therapeutics Inc. and Encourages Investors With Losses to Contact the Firm Business Wire +21.43%
09:30AM  Increased Volume Spurs Stock Prices of Benitec Biopharma, Regulus Therapeutics Accesswire
Mar-24-17 11:50AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Commenced a Class Action on Behalf of Shareholders of Regulus Therapeutics Inc. Lead Plaintiff Deadline of April 3, 2017 Accesswire +12.00%
11:28AM  INVESTOR NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
10:29AM  DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Regulus Therapeutics Inc. (RGLS) and Lead Plaintiff Deadline - April 3, 2017 Accesswire
Mar-22-17 10:54AM  INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
09:46AM  INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Commenced a Class Action on Behalf of Shareholders of Regulus Therapeutics Inc. Lead Plaintiff Deadline of April 3, 2017 Business Wire
Mar-20-17 10:38AM  SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm Accesswire -7.84%
10:28AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Regulus Therapeutics Inc. (RGLS) and Lead Plaintiff Deadline - April 3, 2017 Accesswire
Mar-17-17 07:29PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regulus Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline RGLS GlobeNewswire
10:58AM  SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
09:00AM  RGLS INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Regulus Therapeutics Inc. and a Lead Plaintiff Deadline of April 3, 2017 Business Wire
Mar-15-17 12:32PM  INVESTOR NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm Accesswire -7.14%
10:27AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Regulus Therapeutics Inc. (RGLS) and Lead Plaintiff Deadline: April 3, 2017 Accesswire
Mar-14-17 12:08PM  INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
Mar-13-17 12:00PM  RGLS SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Regulus Therapeutics Inc. and a Lead Plaintiff Deadline of April 3, 2017 PR Newswire +8.00%
Mar-09-17 01:04PM  IMPORTANT ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
10:27AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Regulus Therapeutics Inc. (RGLS) and Lead Plaintiff Deadline: April 3, 2017 Accesswire
Mar-08-17 01:04PM  REGULUS THERAPEUTICS INC. Financials +13.04%
12:14PM  IMPORTANT SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
11:02AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Commenced a Class Action on Behalf of Shareholders of Regulus Therapeutics Inc. Lead Plaintiff Deadline of April 3, 2017 Business Wire
09:00AM  DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Regulus Therapeutics Inc. To Contact The Firm Business Wire
Mar-06-17 01:20PM  IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
Mar-03-17 08:10PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regulus Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline - RGLS Accesswire
10:23AM  RGLS SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Regulus Therapeutics Inc. and a Lead Plaintiff Deadline of April 3, 2017 Business Wire
06:09AM  REGULUS THERAPEUTICS INC. Files SEC form 10-K, Annual Report
Mar-02-17 10:14PM  Edited Transcript of RGLS earnings conference call or presentation 2-Mar-17 10:00pm GMT
04:55PM  Regulus reports 4Q loss
04:22PM  REGULUS THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:10PM  Regulus Reports Fourth Quarter 2016 Financial Results and Pipeline Update PR Newswire
07:07AM  Q4 2016 Regulus Therapeutics Inc Earnings Release - After Market Close
Feb-28-17 02:55PM  IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
10:10AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Regulus Therapeutics Inc. (RGLS) & Lead Plaintiff Deadline: April 3, 2017 GlobeNewswire
Feb-27-17 12:48PM  IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
12:04PM  RGLS INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Regulus Therapeutics Inc. and a Lead Plaintiff Deadline of April 3, 2017 GlobeNewswire
11:03AM  IMPORTANT EQUITY NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WRIGHT TIMOTHY MICHAELChief R & D OfficerJul 25Buy0.91274,725250,000274,725Jul 25 06:09 PM
RASTETTER WILLIAM HDirectorJul 25Buy0.91274,725250,000624,625Jul 25 06:09 PM
Hagan Joseph PPresident and CEOJul 25Buy0.91219,780200,000241,297Jul 25 06:08 PM
PAPADOPOULOS STELIOSDirectorJul 25Buy0.911,000,000910,0001,770,677Jul 25 06:06 PM
Chevallard Daniel R.Chief Financial OfficerJul 25Buy0.9154,94550,00059,415Jul 25 06:07 PM